This case series provides the first reported evidence of an association between truncating TTN variants and chemotherapy-induced cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
TTN truncating variants may predispose to chemotherapy-induced cardiomyopathy; leaves open whether genetic screening should inform anthracycline decisions.
Linschoten et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: